Epsilogen
Develops IgE, IgA and IgG antibody therapeutics for cancer, with lead candidate MOv18 IgE in a Phase Ib trial in platinum-resistant ovarian cancer.
epsilogen.com ↗Why it's here
King's College London spinout that raised £43.25M in total Series B funding, including a £12.5M extension in September 2024 from existing investors such as Novartis Venture Fund and British Patient Capital.
source: samedanltd.com- Focus
- Cancer antibodies
- Founded
- 2016
- Latest round
- Series B extension, £12.5M, Sep 2024
- Staff (Companies House accounts)
- 22, average over the period to 31 Dec 2025source: find-and-update.company-information.service.gov.uk
- London office
- Waterfront, ARC West London, Manbre Road, Hammersmith, London W6 9RH, Hammersmith and Fulham W6 9RHsource: epsilogen.com
- London presence
- HQsource: tech.eu
- Investors
- 3B Future Health Fund, ALSA Ventures, British Patient Capital, Epidarex Capital, Novartis Venture Fund, Schroders Capitalsource: samedanltd.com
- Nearest station
- Hammersmith, 764 m
- Visas
- Licensed visa sponsor, listed as Epsilogen Ltdsource: gov.uk
- Elsewhere
- LinkedIn ↗
Verified 8 Oct 2026. How we verify · Suggest a fix
For Epsilogen
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/epsilogen"><img src="https://londonmempool.co.uk/badge/epsilogen.svg" alt="Epsilogen is listed on London Mempool" width="357" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.